Stakeholder perspectives on a risk-benefit framework for genetic testing (Q35546409)

8 August 2017

title

Stakeholder perspectives on a risk-benefit framework for genetic testing (English)

1 reference

8 August 2017

3

Wylie Burke

1 reference

8 August 2017

6

David L Veenstra

1 reference

8 August 2017

Joshua A Roth

1

1 reference

8 August 2017

Louis P Garrison

series ordinal

2

1 reference

8 August 2017

Scott D Ramsey

series ordinal

4

1 reference

8 August 2017

Rick Carlson

series ordinal

5

1 reference

8 August 2017

publication date

20 April 2010

1 reference

8 August 2017

published in

Public Health Genomics

1 reference

8 August 2017

volume

14

1 reference

8 August 2017

issue

2

1 reference

8 August 2017

page(s)

59-67

1 reference

A policy model to evaluate the benefits, risks and costs of warfarin pharmacogenomic testing

8 August 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3214932

Is the United States ready for QALYs?

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3214932

Personal utility and genomic information: look before you leap

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3214932

Challenges of translating genetic tests into clinical and public health practice

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3214932

Recommendations from the EGAPP Working Group: can tumor gene expression profiling improve outcomes in patients with breast cancer?

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3214932

The critical path of warfarin dosing: finding an optimal dosing strategy using pharmacogenetics

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3214932

Influence of CYP2C9 and VKORC1 1173C/T genotype on the risk of hemorrhagic complications in African-American and European-American patients on warfarin

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3214932

Assessing a structured, quantitative health outcomes approach to drug risk-benefit analysis

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3214932

Three approaches to qualitative content analysis

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3214932

Implications of the genetics revolution for health services research: pharmacogenomics and improvements in drug therapy

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3214932

Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3214932

Good research practices for measuring drug costs in cost-effectiveness analyses: a societal perspective: the ISPOR Drug Cost Task Force report--Part II.

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3214932

The use of QALYs in clinical and patient decision-making: issues and prospects.

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3214932

Warfarin and pharmacogenomic testing: the case for restraint

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3214932

Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3214932

Relative impact of covariates in prescribing warfarin according to CYP2C9 genotype

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3214932

Use of pharmacogenetics and clinical factors to predict the maintenance dose of warfarin.

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3214932

The incidence of adverse drug events in two large academic long-term care facilities

26 September 2018

1 reference

Crossref

https://api.crossref.org/works/10.1159%2F000290452

Promoting safe and effective genetic testing in the United States. Final report of the Task Force on Genetic Testing

21 January 2018

1 reference

12 December 2020

Economic analysis in healthcare decisions

1 reference

12 December 2020

Update on the methods of the U.S. Preventive Services Task Force: insufficient evidence

1 reference

12 December 2020

Editorial: On the benefits of modeling using QALYs for societal resource allocation: the model is the message

1 reference

12 December 2020

Editorial: Moving the QALY forward or just stuck in traffic?

1 reference

12 December 2020

Identifiers

DOI

10.1159/000290452

1 reference

release_5cruqhthibaofnh6zpmppdta6e

8 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/5cruqhthibaofnh6zpmppdta6e

24 November 2022

mapped directly with Wikidata item

PMC publication ID

3214932

1 reference

8 August 2017

1 reference